2023 PEPR MIE recipients : CIRI involved in 6 projects
About the PEPR MIE
The PEPR MIE call for projects (priority research programs and equipment for emerging infectious diseases) is managed by Inserm through the ANRS Emerging Infectious Diseases Program. It is part of the Innovation santé 2030 (France 2030) plan, which aims to strengthen French and European preparedness and response capacity in the event of a new health crisis. As part of a "One Health" approach, it funds interdisciplinary projects, with a total budget of 22 million euros.
The objectives are threefold. The aim is to gain a better understanding of the emergence or re-emergence of infectious diseases, in order to develop diagnostic, protection and treatment tools. In addition, one axis focuses on the implementation of health policies based on scientific evidence and adapted to the specific context of the crisis.
The PEPR MIE is divided into three components:
- Component 1: Accelerating the acquisition of fundamental knowledge on emerging infectious diseases
- Component 2: Promote innovation and develop new treatments, vaccines and other prevention, diagnostic and surveillance tools for emerging infectious diseases.
- Component 3: Enable public policies and society to cope with epidemic crises
2023 laureates projects that involve the ciri
Three projects led by a CIRI researcher
Thomas HENRY (Inserm, I2BA team) is coordinating the Ft6SS-Meca project (component 1).
The Ft6SS-Meca project will study the structure, molecular mechanisms of secretion and function of effectors of the secretion system (T6SS) of the bacterium Francisella tularensis (threat agent). The expected results could lead to the long-term identification of new treatments specifically targeting this secretion system, a key virulence factor.
Sylvain BAIZE (Institut Pasteur, UBIVE team) coordinates the COPAFLICT project (component 1).
The aim of the COPAFLICT project is to improve fundamental knowledge of viral hemorrhagic fevers and offer new perspectives for their diagnosis and treatment. To achieve this, it will study the immunopathogenesis associated with Lassa fever virus (lightning hemorrhagic fever), to identify immune pathways of interest for the development of new therapeutic strategies targeting the host response.
Alexandre GAYMARD (HCL, VirPath team) coordinates the VORTEX project (component 2).
Sophie JARRAUD (HCL, LegioPath team) and Sophie TROUILLET-ASSANT (HCL, VirPath team) are also part of the VORTEX consortium.
The aim of the VORTEX project is to develop a non-invasive diagnostic method based on the results of patients' exhaled air analysis. It aims to identify signatures of volatile organic compounds specific to a pathogen or to the immune response of patients, in order to improve the management and monitoring of emerging respiratory infections.
Three projects involving CIRI researchers in their consortium
Oliver TERRIER (ENS de Lyon, Université Claude Bernard Lyon 1, VirPath team) is part of the consortium behind the 3D-LUNGO project (component 1).
Coordinated by Lisa CHAKRABARTI (Institut Pasteur), this project aims to provide 3D tissue models, based on the study of the susceptibility of nasal or bronchial mucosa and pulmonary alveoli to respiratory viruses, to rapidly and collaboratively test the lesions that could be induced by newly emerging respiratory pathogens.
Bruno LINA (Institut des Agents Infectieux, HCL - Hopital de la Croix-Rousse, VirPath team) is part of the consortium behind the SISP&EAU project (component 1).
Coordinated by Pierre-Yves BOELLE (Institut Pierre Louis d'Epidemiologie et de Santé Publique, Sorbonne Université), this project aims to build and validate a surveillance model for respiratory viruses in France, integrating clinical cases and wastewater. It will set up the detection and monitoring of viral strains causing respiratory infections to characterize the dynamics of virus circulation in the general population. It will perpetuate the technological, mathematical and IT tools developed for epidemiological surveillance during the COVID-19 pandemic.
Cyrille Mathieu (CIRI Centre International de Recherche en Infectiologie, Inserm, CNRS, ENS Lyon, Univ. Claude Bernard Lyon 1, NITROVIRE group), Pierre-Olivier VIDALAIN (Inserm, CNRS, ENS, Université Claude Bernard Lyon 1, VIRIMI team) and Vincent LOTTEAU (Inserm, VIRIMI team) are part of the consortium behind the NIPAH-LISA project (part 2).
Coordinated by Sonia LONGHI (Aix Marseille Université, CNRS), this project focuses on airborne infections by viruses of the highly pathogenic Paramyxovirinae family (including Nipah virus), and aims to develop a multi-component antiviral treatment for these infections.
Congratulations to all the winners!
See more information and the list of all winning projects on the ANRS website.
Source : ANRS.fr
Translated with DeepL